Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody

European Journal of Cancer

Volumn 66, Issue , 2016, Pages 91-94

  Michot, Jean Marie ^a   Mazeron, Renaud ^a   Dercle, Laurent ^a   Ammari, Samy ^a   Canova, Charles ^a   Marabelle, Aurelien ^a   Rose, Shelonitda ^b   Rubin, Eric ^b   Deutsch, Eric ^a   Soria, Jean Charles ^a   Ribrag, Vincent ^a   Levy, Antonin ^a,c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Abscopal effect; Hodgkin disease; Irradiation; Out of field; PD 1; Pembrolizumab

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CARMUSTINE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PEMBROLIZUMAB; VINBLASTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PODOPHYLLOTOXIN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLYCOLYSIS; HODGKIN DISEASE; HUMAN; LETTER; LYMPHADENOPATHY; MALE; MEDIASTINUM LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; TUMOR VOLUME; CASE REPORT; IMMUNOLOGY; METASTASIS; PATHOLOGY; PROCEDURES; REMISSION; SALVAGE THERAPY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYTARABINE; HODGKIN DISEASE; HUMANS; MALE; MELPHALAN; NEOPLASM METASTASIS; PODOPHYLLOTOXIN; PROGRAMMED CELL DEATH 1 RECEPTOR; REMISSION INDUCTION; SALVAGE THERAPY;

EID: 84982124874     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.06.017     Document Type: Letter

References (9)

1. [1] Formenti, S.C., Demaria, S., Systemic effects of local radiotherapy. Lancet Oncol 10 (2009), 718–726.
2. [2] Postow, M.A., Callahan, M.K., Barker, C.A., Yamada, Y., Yuan, J., Kitano, S., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366 (2012), 925–931.
3. [3] Park, S.S., Dong, H., Liu, X., Harrington, S.M., Krco, C.J., Grams, M.P., et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res 3 (2015), 610–619.
4. [4] Ansell, S.M., Lesokhin, A.M., Borrello, I., Halwani, A., Scott, E.C., Gutierrez, M., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372 (2015), 311–319.
5. [5] Dewan, M.Z., Galloway, A.E., Kawashima, N., Dewyngaert, J.K., Babb, J.S., Formenti, S.C., et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res Off J Am Assoc Cancer Res 15 (2009), 5379–5388.
6. [6] Chiang, C.S., Fu, S.Y., Wang, S.C., Yu, C.F., Chen, F.H., Lin, C.M., et al. Irradiation promotes an m2 macrophage phenotype in tumor hypoxia. Front Oncol, 2, 2012, 89.
7. [7] Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R.R., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124 (2014), 687–695.
8. [8] Levy, A., Chargari, C., Marabelle, A., Perfettini, J.L., Magné, N., Deutsch, E., Can immunostimulatory agents enhance the abscopal effect of radiotherapy?. Eur J Cancer 62 (2016), 36–45.
9. [9] Sharabi, A.B., Lim, M., DeWeese, T.L., Drake, C.G., Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol, 16, 2015 e498–e509.